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Abstract
Background: Chronic inflammation is a hallmark of type-2 diabetes (T2D) and asthma. Monocyte chemoattractant
protein (MCP)-1 or CCL-2 is a key regulator of monocytic infiltration into the sites of inflammation. The changes in
systemic MCP-1 levels and its relationship with other inflammatory/immune markers in T2D patients with asthma
remain unclear and have been addressed in this study.
Methods: Plasma samples from 10 asthmatic T2D patients (Group I: BMI = 37.82 ± 9.75 kg/m2), 13 non-asthmatic
T2D patients (Group II: BMI = 32.68 ± 4.63 kg/m2), 23 asthma patients without T2D (Group III: BMI = 30.14 ± 6.74 kg/m2),
and 25 non-asthmatic non-diabetic controls (Group IV: BMI = 27.99 ± 5.86 kg/m2) were used to measure levels of MCP-
1 and multiple cytokine/chemokine biomarkers with bead-based multiplex assays using Luminex technology. IgE/ECP
were measured using commercial ELISA kits. Data (mean ± SEM) were compared using unpaired Student’s t-test and
linear dependence between two variables was assessed by Pearson’s correlation coefficient (r) and P ≤ 0.05
was considered as significant.
Results: Plasma MCP-1 levels were significantly higher in Group I (337.95 ± 46.40 pg/mL) as compared with Group II
(216.69 ± 17.30 pg/mL), Group III (251.76 ± 19.80 pg/mL), and Group IV (223.52 ± 133.36 pg/mL). MCP-1 showed
differential association with tested biomarkers by correlating positively with: (i) IFN-α2, IL-10, fractalkine, and VEGF in
T2D patients with asthma; (ii) IL-6 and GRO-α in T2D patients without asthma; (iii) MDC, IP-10, GM-CSF, FGF-2,
and PDGF-AA/BB in patients with asthma only; and (iv) FPG and TG in non-asthmatic non-diabetic controls.
MCP-1 associated with IL-1RA only in subjects with asthma.
Conclusion: The systemic MCP-1 levels were significantly elevated in T2D patients with asthma as compared
with those without asthma and/or diabetes while these changes correlated differentially with important biomarkers of
inflammation and airway remodeling.
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Background
The increasing evidence suggests that chronic inflamma-
tion is a critical factor involved in type-2 diabetes (T2D)
and asthma [1–5]. Monocyte chemoattractant protein
(MCP)-1, also known as C-C chemokine ligand (CCL)-2,
recruits monocytes to the sites of inflammation, such as
into the expanding adipose tissue in obesity/T2D [6, 7]
or the arterial vessel wall in asthmatic patients [8].
MCP-1, which is associated with a myriad of diseases in-
cluding allergic asthma, multiple sclerosis, rheumatoid
arthritis, atherosclerosis, and insulin-resistant diabetes,
is produced by many cell types such as endothelial and
epithelial cells, fibroblasts, smooth muscle, mesangial,
and microglial cells, however, predominantly by mono-
cytes/macrophages [9].
The lung is also a target organ for diabetic microangiop-
athy and the reduced lung function has been frequently
observed in diabetic patients due to biochemical changes
in the connective tissue as well as non-enzymatic glycosyl-
ation of proteins induced by chronic hyperglycemia
[10, 11]. Thus, the risk of asthma is elevated in the
obese by 2–3 times [12] and in the T2D patients by 2
times [13] as compared with normal subjects. Obesity
seems to be the major contributor to the pathogenesis of
asthma and the increase in abdominal adiposity negatively
impacts the lung volumes and pulmonary and bronchial
expansions during inhalation. Notably, obesity and T2D
are also characterized by oxidative stress and low-grade
chronic inflammation [14]. Since MCP-1 is essentially in-
volved in the pathogenesis of several inflammatory condi-
tions, we hypothesized that it could be a major player of
predictive significance and a sensitive biomarker in T2D
patients with asthma that are also more likely to develop
poor disease prognosis. Therefore, the study objective was
to measure the plasma MCP-1 levels and assess their rela-
tionship with various inflammatory, airway remodeling,
and other immune biomarkers in T2D patients with and
without asthma. This study also included non-diabetic
asthmatic individuals and non-diabetic non-asthmatic
subjects as controls. Herein, we report the significantly
higher MCP-1 levels in asthmatic as compared with non-
asthmatic T2D pateints. Furthermore, plasma MCP-1
levels associated differentially with inflammatory and lung
tissue remodeling biomarkers when compared between
asthmatic T2D patients and other study groups.
Methods
Study population
This study comprised of 23 diabetic and 48 non-diabetic
male/female individuals, further subclassified into 4
groups as follows: Group I including 10 T2D patients with
asthma (age 53.60 ± 7.78 years; BMI 37.82 ± 9.75 kg/m2);
Group II including 13 T2D patients without asthma (age
50.92 ± 6.42 years; BMI 32.68 ± 4.63 kg/m2); Group III
including 23 asthmatic non-diabetic individuals (age
38.70 ± 9.34 years; BMI 30.14 ± 6.74 kg/m2); and Group
IV including 25 non-asthmatic non-diabetic individuals as
controls (age 35.96 ± 8.27 years; BMI 27.99 ± 5.86 kg/m2).
Written informed consent was obtained from all par-
ticipants before enrolment in the study and the study
protocol was approved by Ethical Review Committee
of Dasman Diabetes Institute, Kuwait. Those of age
<18 years. or >65 years. or those suffering from serious
cardiovascular, hepatic, or renal disease, hematologic or
immune disorder, type-1 diabetes, pregnancy, or malig-
nancy were excluded. Clinical and anthropometric charac-
teristics of study participants are summarized in Table 1.
T2D/asthma diagnosis, anthropometric measurements
and biochemical analyses
T2D diagnosis was based on results of (i) fasting plasma
glucose (FPG), (ii) oral glucose tolerance test (OGTT),
and (iii) glycated hemoglobin (HbA1c) test. FPG levels of
≥126 mg/dL (≥7 mmol/L), 2 h-OGTT values of >200 mg/
dL (11.1 mmol/L), and/or HbA1C levels of ≥6.5 % on two
separate tests were diagnosed by attending physician as
T2D. The diagnosis of asthma was based on a compatible
clinical history along with an evidence of reversible airflow
limitation i.e., increase in forced expiratory volume in 1 s
(FEV1) of ≥15 % following a bronchodilator or airway
hyper-responsiveness i.e., provocative concentration of
methacholine causing a 20 % reduction in FEV1. Pulmon-
ary function testing and spirometry were performed ac-
cording to the standards of the American Thoracic
Society [15]. Regarding anthropometric/physical data,
height and weight were measured while barefoot, waist
circumference was measured and the waist-to-hip ratio
was calculated. BMI was calculated as follows: body






Total number (N) 10 13 23 25
Age (Yrs.) 53.60 ± 7.78 50.92 ± 6.42 38.70 ± 9.34 35.96 ± 8.27
BMI (kg/m2) 37.82 ± 9.75 32.68 ± 4.63 30.14 ± 6.74 27.99 ± 5.86
FPG (mmol/L) 9.01 ± 2.57 8.00 ± 2.57 5.37 ± 0.60 5.09 ± 0.65
HbA1c (%) 8.60 ± 1.25 8.20 ± 1.85 5.50 ± 0.42 5.46 ± 0.49
Total cholesterol
(mmol/L)
4.68 ± 0.44 5.03 ± 1.00 4.86 ± 0.86 4.70 ± 0.62
HDL (mmol/L) 1.21 ± 0.32 0.99 ± 0.25 1.20 ± 0.31 1.49 ± 0.73
LDL (mmol/L) 2.82 ± 0.56 3.12 ± 1.13 3.09 ± 0.88 2.93 ± 0.61
TG (mmol/L) 1.44 ± 0.72 1.80 ± 1.21 1.46 ± 1.65 0.82 ± 0.45
BMI body mass index, HbA1c glycated hemoglobin, FPG fasting plasma
glucose, HDL high-density lipoprotein, LDL low-density lipoprotein,
TG triglycerides
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weight (kg)/height (m2). An average of the 3 blood pres-
sure readings (Omron HEM-907XL digital automatic
sphygmomanometer, Omron Healthcare Inc. IL, USA),
taken after 5–10 min rest for each, was obtained. The
whole body composition including body fat percentage,
soft lean mass and total body water was assessed (IOI 353
Body Composition Analyzer, Jawon Medical, South
Korea). Plasma or serum samples were analyzed for FPG,
HbA1c, total cholesterol, high- and low-density lipopro-
teins (HDL, LDL), and triglycerides (TG) levels using
standard methods. Briefly, FPG was measured using hexo-
kinase method, HbA1c was measured using Variant device
(BioRad, Hercules, CA, USA), serum cholesterol by chol-
esterol oxidase-peroxidase-amidopyrine method, HDL
was measured by direct method using polyethylene glycol-
pretreated enzymes, LDL was measured using Friedewald
formula, and serum triglycerides were measured using gly-
cerol phosphate oxidase-peroxidase-amidopyrine method.
Measurement of plasma analytes
A wide range of plasma analytes classified as cytokines,
chemokines, activation and growth factors were measured
using Milliplex MAP human cytokine/chemokine mag-
netic bead panel-immunology (Cat.# HCYTOMAG-60 K,
Milliplex Corp, USA) multiplex immunoassay while some
analytes were measured using commercial enzyme-linked
immunosorbent assays (ELISA) such as immunoglobulin
(Ig)-E (Human IgE Platinum ELISA kit, Cat.# BMS2097,
eBioscience, Austria), and Eosinophil cationic protein
(ECP) (Human ECP kit, Cat.# SK00128-01, Aviscera Bio-
science Inc. CA, USA) and following the manufacturers’
instructions. The tested analytes included interferon
(IFN)-α2, IFN-γ, interleukin (IL)-1α/β, IL-1 receptor agon-
ist (IL-1RA), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12p40/p70, IL-13, IL-15, IL-17A, transforming
growth factor (TGF)-α, tumor necrosis factor (TNF)-α/β,
macrophage chemoattractant protein (MCP)-1, MCP-3,
macrophage inflammatory protein (MIP)-1α or CCL-3,
MIP-1β/CCL-4, regulated on activation normal T-cell
expressed and secreted (RANTES)/CCL-5, eotaxin/CCL-
11, macrophage-derived chemokine (MDC)/CCL-22,
growth-regulated oncogene (GRO) or CXC chemokine
ligand (CXCL)-1, fractalkine/CX3CL-1, IFN-γ-inducible
protein (IP)-10/CXCL-10, epidermal growth factor
(EGF), FMS-like tyrosine kinase-3 ligand (FLT-3 L),
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF),
fibroblast growth factor (FGF)-2, platelet-derived
growth factor (PDGF)-AA/BB, vascular endothelial
growth factor (VEGF), soluble CD40 ligand (sCD40L),
ECP, and IgE. Data were acquired using Luminex
xMAP analyzer (Luminex 100/200 Milliplex Analyzer,
Luminex Corp. USA) following the manufacturer’s in-
structions while a digital processor managed data
output and Milliplex analyst software was used to de-
termine mean fluorescence intensity and analyte con-
centrations (pg/mL).
Statistical analysis
For statistical analysis of the data (mean ± s.e.m.), group
means were compared using unpaired Student’s t-test and
linear dependence between two variables was assessed by
Pearson’s correlation coefficient (r) using GraphPad Prism
software (version 6.05; San Diego, CA, USA); all P-values
≤0.05 were considered statistical significant.
Results
MCP-1 levels are significantly higher in diabetic pateints
with asthma
T2D is a metabolic disorder involving chronic low-grade
systemic inflammation while asthma is a chronic allergic
inflammatory disease of the lung. We asked whether the
plasma levels of MCP-1/CCL-2, which is a signature in-
flammatory marker, were elevated in T2D patients with
asthma as compared with those having either diabetes or
asthma or none of the morbid condition. To this end, as
shown in Fig 1, plasma MCP-1 levels were found to be
significantly higher in T2D patients with asthma (Group
I: 337.95 ± 46.40 pg/mL) as compared with other groups,
such as T2D patients without asthma (Group II: 216.69
± 17.30 pg/mL; P = 0.03), non-diabetic individuals with
asthma (Group III: 251.76 ± 19.80 pg/mL; P = 0.05), and
non-diabetic non-asthmatic controls (Group IV: 223.52
± 13.36 pg/mL; P = 0.003).
Differential association of plasma MCP-1 levels with
markers of inflammation and airway remodeling
Next, we asked if the plasma MCP-1 levels were associ-
ated differentially with various inflammatory and airway
remodeling biomarkers in diabetic/non-diabetic individ-
uals with and without asthma. To this effect, our data
show (Table 2) that in diabetic patients with asthma,
MCP-1 levels correlated with IFN-α2, IL-1RA, IL-10,
Fractalkine/CX3CL-1, and VEGF whereas, in diabetic
patients without asthma, MCP-1 levels correlated with
IL-3, IL-6, IL-9, MIP-1α/CCL-3, MIP-1β/CCL-4, GRO-
α/CXCL-1, and BMI. In non-diabetic individuals with
asthma, MCP-1 levels correlated with IL-1β, IL-1RA,
MDC/CCL-22, IP-10/CXCL-10, GM-CSF, FGF-2,
PDGF-AA, PDGF-BB, and HbA1c. While, in healthy
controls, plasma MCP-1 correlated with IL-1α, IL-1β,
IL-2, IL-3, IL-9, BMI, FPG, HbA1c, and TG levels.
Altogether, MCP-1 associated differentially with the
tested inflammatory and pulmonary remodeling bio-
markers and was found to correlate positively with: (i)
IFN-α2, IL-10, fractalkine, and VEGF in T2D patients
with asthma; (ii) IL-6 and GRO-α in T2D patients with-
out asthma; (iii) MDC, IP-10, GM-CSF, FGF-2, and
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PDGF-AA/BB in patients with asthma only; and (iv)
FPG and TG in non-diabetic non-asthmatic controls.
Besides, MCP-1 correlated positively with IL-1RA only
in asthma patients, irrespective of their diabetes status.
Discussion
In the present study, significantly elevated plasma MCP-
1 levels were observed in T2D patients with asthma
(Group I) as compared with other groups i.e., individuals
with T2D only (Group II, P = 0.03), asthma only (Group
III, P = 0.05), and non-diabetic non-asthmatic controls
(Group IV, P = 0.003). Increased MCP-1 levels have been
previously reported in T2D individuals [8, 16] as well as
in bronchoalveolar lavage fluid from asthmatic patients
[17]. Lung is also a target organ for diabetic microangi-
opathy and the diabetic patients have been reported to
be at a higher risk for asthma, chronic obstructive pul-
monary disease, pulmonary fibrosis and pneumonia [18].
Mononuclear cells such as lymphocytes and monocytes
are involved in systemic and local inflammation in which
circulatory monocytes infiltrate into target tissues such
as white adipose tissue in case of metabolic inflamma-
tion and bronchoalveolar epithelia in asthmatic inflam-
mation. Dandona et al. [13] found the elevated
expression of CCR-2 as well as IL-4 and MMP-9 asthma
mediators in the mononuclear cell fractions from obese
and obese/T2D patients which indicated that these cell
populations were responsive to chemotaxis by chemo-
tactic cytokines such as MCP-1/CCL-2 and eotaxin. We
speculate that MCP-1 may be a key chemokine involved
in monocytic as well as eosinophilic inflammation as
both these cell types express cognate CCR-2 receptor. In
the present study, MCP-1 levels were found to be signifi-
cantly higher in diabetic patients with asthma while no
significant changes in eotaxin levels could be observed
in T2D and/or asthma patients as compared with non-
diabetic non-asthmatic controls. It is noteworthy that
the presence of asthma in addition to T2D led to a fur-
ther increase in plasma levels of only the MCP-1 among
all biomarkers that we tested in this study which sug-
gests that MCP-1 may be a more sensitive immune
marker for disease prognosis in patients inflicted with
inflammatory comorbidities, such as T2D and asthma.
Hence, the MCP-1 mechanistic link between T2D and
asthma may be critical as a risk marker in comorbid in-
flammatory states. Chemokines play an important role
in the pathophysiology of inflammatory diseases includ-
ing asthma, allergy, atherosclerosis, glomerulonephritis,
and obesity/T2D [19]. MCP-1 expression in T2D may be
related to the hyperglycemia as high glucose treatment
of endothelial cells from diabetic subjects resulted in a
40–70 % increase of MCP-1 and a 10–20 % increase of
vascular cell adhesion molecule (VCAM)-1 expression,
suggesting a synergistic enhancement due to monocyte-
endothelial cell interaction [20]. Similarly, another study
showed that high glucose concentrations, advanced gly-
cation end products, glycated albumin, and glycoxidized
LDL upregulated MCP-1 expression in human endothe-
lial cells [21]. The higher MCP-1 levels that we found in
comorbid (asthmatic diabetic) patients may be due to
the reason that both disease conditions involve the
underlying etiologic factor of chronic inflammation
which may become potentiated by a synergistic response
between two morbid states. The previous studies have
pointed to an increased risk for asthma in obesity [22]
and T2D [18, 23]. We speculate that the obese/T2D in-
dividuals with higher systemic and local (broncho-pul-
monary epithelial) expression of MCP-1 may be at a
high risk and more prone to develop asthma and further
studies will be required to verify this line of argument.
In the present study, plasma MCP-1 concentrations
were found to be differentially associated with the tested
inflammatory, airway remodeling, and allergic biomarkers
Fig. 1 Increased plasma monocyte chemoattractant protein (MCP)-1
concentrations in type-2 diabetes (T2D) patients with asthma. Plasma
samples from 10 T2D patients with asthma, 13 T2D patients without
asthma, 23 asthma patients with no diabetes, and 25 non-diabetic
non-asthmatic controls were used to measure MCP-1 concentrations
(pg/mL) using Milliplex MAP human cytokine/chemokine magnetic
bead panel multiplex immunoassay as described in Methods. The
data, represented as group means with SEM, show that plasma MCP-1
concentrations in T2D patients with asthma (337.95 ± 46.40 pg/mL)
were significantly higher than those of T2D patients without asthma
(216.69 ± 17.30 pg/mL P = 0.03), asthma only individuals (251.76 ±
19.80 pg/mL P = 0.05), and non-diabetic non-asthmatic controls
(223.52 ± 13.36 pg/mL P = 0.003)
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in diabetic/non-diabetic individuals, with and without
asthma. Thus, plasma MCP-1 levels correlated positively
with those of: (i) IFN-α2, IL-10, fractalkine, and VEGF in
T2D patients with asthma; (ii) IL-6 and GRO-α in T2D
patients without asthma; (iii) MDC, IP-10, GM-CSF, FGF-
2, and PDGF-AA/BB in asthma only patients; and (iv)
FPG and TG in non-diabetic non-asthmatic individuals.
This association of MCP-1 with all these biomarkers
points to a complex interplay of multiple proteins that
leads to the etiopathogenesis of T2D and/or asthma.
Notably, the MCP-1 link with both fractalkine and VEGF
in T2D patients with asthma reflects its significance as a
risk marker in morbid conditions with complex immuno-
logic phenotype of inflammation and angiogenesis. The
relationship of MCP-1 with more than one growth factors
including GM-CSF, FGF-2, and PDGF as we detected in
asthma only patients is in agreement, at least in part, with
previous reports showing that FGF-2/PDGF and GM-CSF
were detected and important as remodeling and suscepti-
bility biomarkers, respectively, for allergic asthma [24–26].
Table 2 Correlation of plasma MCP-1 with immune and clinical biomarkers
Marker Diabetic Non-diabetic
Asthmatic Non-asthmatic Asthmatic Non-asthmatic
r P r P r P r P
IFN-α2 0.62 0.05* −0.31 0.28 0.38 0.07 −0.31 0.12
IL-1α −0.37 0.46 0.28 0.64 0.18 0.53 −0.57 0.01*
IL-1β 0.16 0.79 0.53 0.63 0.77 0.002** −0.62 0.01*
IL-1RA 0.65 0.03* −0.40 0.17 0.42 0.05* −0.25 0.21
IL-2 −0.40 0.43 −0.76 0.07 0.51 0.07 −0.49 0.03*
IL-3 0.16 0.74 −0.70 0.05* −0.17 0.57 −0.78 0.0002***
IL-6 0.24 0.56 0.64 0.04* 0.39 0.11 −0.11 0.62
IL-9 0.16 0.79 −0.85 0.02* −0.30 0.26 −0.76 0.0004***
IL-10 0.70 0.02* −0.34 0.26 0.27 0.26 0.18 0.38
IL-12p70 0.22 0.52 −0.48 0.09 0.27 0.23 −0.26 0.20
MDC/CCL-22 −0.01 0.97 0.01 0.96 0.44 0.03* 0.37 0.07
MIP-1α/CCL-3 0.07 0.87 −0.62 0.02* −0.01 0.96 0.20 0.35
MIP-1β/CCL-4 0.38 0.27 −0.64 0.02* 0.15 0.48 −0.19 0.40
RANTES/CCL-5 −0.02 0.97 0.05 0.90 0.57 0.06 0.01 0.97
GRO-α/CXCL-1 0.47 0.16 0.54 0.05* 0.22 0.30 0.10 0.62
IP-10/CXCL-10 0.57 0.08 0.16 0.61 0.72 <0.0001*** 0.18 0.37
Fractalkine 0.70 0.02* −0.42 0.14 0.28 0.18 −0.30 0.14
G-CSF 0.38 0.27 −0.49 0.08 0.34 0.11 −0.07 0.71
GM-CSF 0.49 0.15 −0.37 0.20 0.54 0.007** −0.27 0.17
FGF-2 0.40 0.24 −0.12 0.68 0.53 0.01* 0.10 0.62
PDGF-AA −0.39 0.51 0.11 0.74 0.68 0.04* −0.39 0.20
PDGF-BB 0.11 0.89 −0.01 0.97 0.91 0.03* −0.48 0.12
VEGF 0.71 0.02* −0.005 0.99 0.26 0.21 0.09 0.65
FLT-3 L −0.30 0.55 −0.61 0.07 0.01 0.99 −0.16 0.50
IgE 0.61 0.06 −0.39 0.38 0.25 0.26 0.19 0.57
BMI (kg/m2) −0.19 0.59 −0.54 0.05* 0.18 0.39 0.40 0.04*
FPG (mmol/L) −0.11 0.74 0.20 0.51 0.40 0.06 0.46 0.02*
HbA1c (%) 0.03 0.93 −0.24 0.42 0.47 0.02* 0.40 0.05*
TG (mmol/L) 0.25 0.47 −0.12 0.68 0.21 0.31 0.48 0.01*
IFN Interferon, IL interleukin, CCL CC chemokine ligand, CXCL CXC chemokine ligand, MDC macrophage derived chemokine, MIP macrophage inflammatory
protein, RANTES regulated on activation, normal T-cell expressed and secreted, GRO growth regulated oncogene, IP IFN-γ-inducible protein, G-CSF granulocyte
colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, FGF fibroblast growth factor, PDGF platelet derived growth factor, VEGF
vascular endothelial growth factor, FLT-3 L FMS-like tyrosine kinase 3 ligand, IgE immunoglobulin E
All statistical values are indicated in boldface
*significant, **highly significant, ***extremely significant
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In contrast to the study reporting a positive correlation
between MCP-1 gene expression and BMI in obesity/T2D
[27], we did not find a positive association between plasma
MCP-1 levels and obesity/T2D clinical markers such as
BMI, FPG, HbA1c, and TG in our diabetic cohort. In
agreement with our results, Herder et al. reported data
from 236 T2D patients, 242 subjects with impaired glu-
cose tolerance, and 244 normoglycemic controls indicat-
ing that the MCP-1 levels were not associated with
impaired glucose tolerance, T2D or several parameters of
obesity [28]. Our data further show that in asthma pa-
tients, irrespective of their T2D status, MCP-1 associated
positively also with IL-1RA which is an important indica-
tor of the anti-inflammatory competency of these individ-
uals while the IL-1β/IL-1RA balance plays a key role in
asthmatic inflammation. The IgE-mediated stimulation of
mast cells has been shown to induce IL-1RA expression
[29]. Interestingly, in our study, MCP-1 also showed a
positive association with IgE levels (r = 0.61) in diabetic in-
dividuals with asthma; however, it did not approach the
level of significance (P = 0.06). Overall, our data indicate
that plasma MCP-1 levels associate selectively with a wide
range of inflammatory cytokines/chemokines, growth/ac-
tivation factors and could, therefore, be important as a
biomarker for asthma in diabetic and non-diabetic sub-
jects while this association of plasma MCP-1 with asthma
appears to be driven by the conventional risk factors for
inflammation and pulmonary tissue remodeling.
Conclusion
In summary, our data show that plasma MCP-1 levels
were significantly elevated in T2D patients with asthma
as compared with those without asthma, and these
changes in the systemic MCP-1 related differentially
with important biomarkers of inflammation and airway
remodeling. Nonetheless, further studies involving larger
study cohorts as well as other parameters which might
affect inflammation but were not addressed in our study,
such as drug therapy will be required to understand the
functional significance of MCP-1 in asthma.
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